Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication
- PMID: 23106931
- PMCID: PMC4268861
- DOI: 10.1111/j.1360-0443.2012.04043.x
Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication
Abstract
Aim: To examine hepatic enzyme test results throughout the course of pregnancy in women maintained on methadone or buprenorphine.
Design: Participants were randomized to either methadone or buprenorphine maintenance. Blood chemistry tests, including liver transaminases and hepatitis C virus (HCV) status, were determined every 4 weeks and once postpartum. As part of a planned secondary analysis, generalized mixed linear models were conducted with aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) as the dependent variables.
Setting: Six US sites and one European site that provided comprehensive treatment to pregnant opioid-dependent women.
Participants: A total of 175 opioid-dependent pregnant women enrolled in the Maternal Opioid Treatment: Human Experimental Research (MOTHER) study.
Findings: ALT, AST and GGT levels decreased for all subjects across pregnancy trimesters, rising slightly postpartum. HCV-positive subjects exhibited higher transaminases at all time-points compared to HCV-negative subjects, regardless of medication (all Ps < 0.05) condition. Both HCV-positive and negative buprenorphine-maintained participants exhibited lower GGT levels than those who were methadone-maintained (P < 0.05).
Conclusions: Neither methadone nor buprenorphine appear to have adverse hepatic effects in the treatment of pregnant opioid-dependent women.
Trial registration: ClinicalTrials.gov NCT00271219.
© 2012 The Authors, Addiction © 2012 Society for the Study of Addiction.
Conflict of interest statement
The clinical trial was registered with
H.J. discloses that she has received reimbursement for time and travel from Reckitt Benckiser.
KEO’G discloses that he has received reimbursement for time from Reckitt Benckiser.
Figures
References
-
- National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–43. - PubMed
-
- Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750–5. - PubMed
-
- Ling W, Charuvastra C, Collins JF, Batki S, Brown LS, Kintaudi P, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter randomized clinical trial. Addiction. 1998;93:475–86. - PubMed
-
- Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98:441–52. - PubMed
-
- Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opiate dependence. Am J Psychiatry. 1994;151:1025–30. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- R01 DA 015738/DA/NIDA NIH HHS/United States
- R01 DA 018417/DA/NIDA NIH HHS/United States
- R01 DA 15832/DA/NIDA NIH HHS/United States
- R01 DA015764/DA/NIDA NIH HHS/United States
- R01 DA 015778/DA/NIDA NIH HHS/United States
- M01 RR 00095/RR/NCRR NIH HHS/United States
- R01 DA 015741/DA/NIDA NIH HHS/United States
- R01 DA 015764/DA/NIDA NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- R01 DA 018410/DA/NIDA NIH HHS/United States
- R01 DA015738/DA/NIDA NIH HHS/United States
- M01 RR000109/RR/NCRR NIH HHS/United States
- M01 RR 109/RR/NCRR NIH HHS/United States
- R01 DA 017513/DA/NIDA NIH HHS/United States
- R01 DA018417/DA/NIDA NIH HHS/United States
- R01 DA018410/DA/NIDA NIH HHS/United States
- R01 DA015778/DA/NIDA NIH HHS/United States
- R01 DA015832/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
